Eli Lilly expanded its LillyDirect direct-to-consumer pharmacy program on August 18, 2025, adding reduced cash-pay pricing for tirzepatide in single-dose vial formats. Pricing varies by dose strength but lands in the $399–$599 monthly range for the lower doses — meaningfully below the ~$1,000–$1,200 list price of the standard pen formulation, though still above compounded-tirzepatide cash pricing from the most aggressive telehealth programs.
The move is best understood as Lilly defending the brand-name market against compounded competition by lowering the cost barrier to authentic Mounjaro/Zepbound. It also has a clinical rationale: vial-format dispensing improves dose flexibility and reduces waste vs the fixed-dose pen.
For our 2026 rankings, LillyDirect is not itself a "telehealth provider" in the rubric sense (it is a manufacturer cash-pay channel), but several reviewed providers can route eligible patients to it where appropriate.